SG11201809725TA - Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist - Google Patents
Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonistInfo
- Publication number
- SG11201809725TA SG11201809725TA SG11201809725TA SG11201809725TA SG11201809725TA SG 11201809725T A SG11201809725T A SG 11201809725TA SG 11201809725T A SG11201809725T A SG 11201809725TA SG 11201809725T A SG11201809725T A SG 11201809725TA SG 11201809725T A SG11201809725T A SG 11201809725TA
- Authority
- SG
- Singapore
- Prior art keywords
- road
- serene
- avenue
- international
- banjara
- Prior art date
Links
- 108091005435 5-HT6 receptors Proteins 0.000 title 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 title 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 239000004783 Serene Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 2
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641017203 | 2016-05-18 | ||
| PCT/IB2016/054674 WO2017199072A1 (en) | 2016-05-18 | 2016-08-03 | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809725TA true SG11201809725TA (en) | 2018-12-28 |
Family
ID=56940099
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809725TA SG11201809725TA (en) | 2016-05-18 | 2016-08-03 | Combination of pure 5-ht6 receptor antagonists with nmda receptor antagonist |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US11116764B2 (ru) |
| EP (1) | EP3458040B1 (ru) |
| JP (1) | JP6606298B2 (ru) |
| KR (1) | KR102023748B1 (ru) |
| CN (1) | CN109069449A (ru) |
| AU (1) | AU2016407428B2 (ru) |
| BR (1) | BR112018073396A2 (ru) |
| CA (1) | CA3023828C (ru) |
| DK (1) | DK3458040T3 (ru) |
| EA (1) | EA036301B1 (ru) |
| HK (1) | HK1258023A1 (ru) |
| HR (1) | HRP20210640T1 (ru) |
| HU (1) | HUE055083T2 (ru) |
| IL (1) | IL262816B (ru) |
| MX (1) | MX2018013969A (ru) |
| NZ (1) | NZ747778A (ru) |
| SG (1) | SG11201809725TA (ru) |
| WO (1) | WO2017199072A1 (ru) |
| ZA (1) | ZA201807311B (ru) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA202090127A1 (ru) * | 2017-07-03 | 2020-04-15 | Сувен Лайф Сайенсиз Лимитед | Новые применения чистого антагониста 5-htрецептора |
| WO2021111330A1 (en) * | 2019-12-02 | 2021-06-10 | Suven Life Sciences Limited | Treating behavioral and psychological symptoms in dementia patients |
| KR20220110518A (ko) * | 2019-12-02 | 2022-08-08 | 수벤 라이프 사이언시스 리미티드 | 치매 환자의 행동 및 심리적 증상 치료 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2310243T3 (es) * | 2002-11-28 | 2009-01-01 | Suven Life Sciences Limited | Indoles n-aril-3-sulfonil sustituidos que tienen afinidad por receptores de serotonina, proceso para su preparacion y composicion farmaceutica que los contiene. |
| EP1902733A1 (en) * | 2006-09-19 | 2008-03-26 | Laboratorios Del Dr. Esteve, S.A. | Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity |
| US9540321B2 (en) * | 2013-12-02 | 2017-01-10 | Suven Life Sciences Limited | Process for large scale production of 1-[(2-bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole dimesylate monohydrate |
-
2016
- 2016-08-03 EP EP16766623.9A patent/EP3458040B1/en active Active
- 2016-08-03 US US16/097,458 patent/US11116764B2/en active Active
- 2016-08-03 HU HUE16766623A patent/HUE055083T2/hu unknown
- 2016-08-03 KR KR1020187035901A patent/KR102023748B1/ko active IP Right Grant
- 2016-08-03 DK DK16766623.9T patent/DK3458040T3/da active
- 2016-08-03 MX MX2018013969A patent/MX2018013969A/es unknown
- 2016-08-03 WO PCT/IB2016/054674 patent/WO2017199072A1/en active Search and Examination
- 2016-08-03 EA EA201892583A patent/EA036301B1/ru unknown
- 2016-08-03 CN CN201680085559.6A patent/CN109069449A/zh active Pending
- 2016-08-03 AU AU2016407428A patent/AU2016407428B2/en active Active
- 2016-08-03 JP JP2018559283A patent/JP6606298B2/ja active Active
- 2016-08-03 BR BR112018073396-2A patent/BR112018073396A2/pt not_active Application Discontinuation
- 2016-08-03 SG SG11201809725TA patent/SG11201809725TA/en unknown
- 2016-08-03 CA CA3023828A patent/CA3023828C/en active Active
- 2016-08-03 NZ NZ747778A patent/NZ747778A/en unknown
-
2018
- 2018-10-31 ZA ZA2018/07311A patent/ZA201807311B/en unknown
- 2018-11-06 IL IL262816A patent/IL262816B/en active IP Right Grant
-
2019
- 2019-01-10 HK HK19100394.1A patent/HK1258023A1/zh unknown
-
2021
- 2021-04-22 HR HRP20210640TT patent/HRP20210640T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201807311B (en) | 2020-01-29 |
| WO2017199072A1 (en) | 2017-11-23 |
| US11116764B2 (en) | 2021-09-14 |
| CA3023828A1 (en) | 2017-11-23 |
| JP2019516696A (ja) | 2019-06-20 |
| AU2016407428A1 (en) | 2018-11-29 |
| KR20180136566A (ko) | 2018-12-24 |
| US20190175586A1 (en) | 2019-06-13 |
| NZ747778A (en) | 2020-03-27 |
| EP3458040B1 (en) | 2021-01-27 |
| HRP20210640T1 (hr) | 2021-06-25 |
| EA201892583A1 (ru) | 2019-04-30 |
| HUE055083T2 (hu) | 2021-10-28 |
| JP6606298B2 (ja) | 2019-11-13 |
| KR102023748B1 (ko) | 2019-09-20 |
| EA036301B1 (ru) | 2020-10-23 |
| EP3458040A1 (en) | 2019-03-27 |
| AU2016407428B2 (en) | 2019-11-21 |
| HK1258023A1 (zh) | 2019-11-01 |
| IL262816B (en) | 2020-05-31 |
| BR112018073396A2 (pt) | 2019-03-19 |
| IL262816A (en) | 2018-12-31 |
| MX2018013969A (es) | 2019-03-21 |
| CA3023828C (en) | 2019-08-27 |
| CN109069449A (zh) | 2018-12-21 |
| DK3458040T3 (da) | 2021-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908670SA (en) | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators | |
| SG11201901525XA (en) | Muscarinic m1 receptor positive allosteric modulators | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201810485SA (en) | Substituted carbonucleoside derivatives useful as anticancer agents | |
| SG11201903938XA (en) | Acylated glp-1/glp-2 dual agonists | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201408140QA (en) | Crystalline forms of an androgen receptor modulator | |
| SG11201810352XA (en) | New antibacterial compounds | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201809470RA (en) | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201407988UA (en) | Process for improved opioid synthesis | |
| SG11201909735YA (en) | Therapeutic compounds and compositions, and methods of use thereof | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201806424TA (en) | Therapeutic compounds | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201906767XA (en) | Estrogen receptor modulators | |
| SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
| SG11201910043PA (en) | Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof |